[HTML][HTML] Multicenter case–control study of COVID-19–associated mucormycosis outbreak, India
In support of improving patient care, this activity has been planned and implemented by
Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited with …
Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited with …
Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and …
Summary COVID-19-associated pulmonary mucormycosis (CAPM) remains an
underdiagnosed entity. Using a modified Delphi method, we have formulated a consensus …
underdiagnosed entity. Using a modified Delphi method, we have formulated a consensus …
Epidemiology, modern diagnostics, and the management of mucorales infections
D Pham, AR Howard-Jones, R Sparks, M Stefani… - Journal of Fungi, 2023 - mdpi.com
Mucormycosis is an uncommon, yet deadly invasive fungal infection caused by the
Mucorales moulds. These pathogens are a WHO-assigned high-priority pathogen group, as …
Mucorales moulds. These pathogens are a WHO-assigned high-priority pathogen group, as …
Risk factors, mortality, and predictors of survival in COVID-19-associated pulmonary mucormycosis: a multicentre retrospective study from India
Objectives To compare COVID-19-associated pulmonary mucormycosis (CAPM) with
COVID-19-associated rhino-orbital mucormycosis (CAROM), ascertain factors associated …
COVID-19-associated rhino-orbital mucormycosis (CAROM), ascertain factors associated …
Treatment of pulmonary mucormycosis with adjunctive nebulized amphotericin B (MUCONAB trial): Results of an open‐label randomized controlled trial
Background The role of nebulized amphotericin B (NAB) in managing pulmonary
mucormycosis (PM) is unknown. Methods In this open‐label trial, we randomized PM …
mucormycosis (PM) is unknown. Methods In this open‐label trial, we randomized PM …
COVID-19-associated pulmonary mucormycosis
V Krishna, N Bansal, J Morjaria, S Kaul - Journal of Fungi, 2022 - mdpi.com
COVID-19-associated mucormycosis (CAM) emerged as an epidemic in certain parts of the
world amidst the global COVID-19 pandemic. While rhino–orbital mucormycosis was well …
world amidst the global COVID-19 pandemic. While rhino–orbital mucormycosis was well …
[HTML][HTML] Invasive respiratory fungal infections in COVID-19 critically ill patients
F Raffaelli, ES Tanzarella, G De Pascale… - Journal of Fungi, 2022 - mdpi.com
Patients with coronavirus disease 19 (COVID-19) admitted to the intensive care unit (ICU)
often develop respiratory fungal infections. The most frequent diseases are the COVID-19 …
often develop respiratory fungal infections. The most frequent diseases are the COVID-19 …
Risk factors for pulmonary mucormycosis in subjects with diabetes mellitus—A case‐control study
Background Factors associated with pulmonary mucormycosis (PM) among subjects with
diabetes mellitus (DM) remain unclear. Following the coronavirus disease (COVID‐19) …
diabetes mellitus (DM) remain unclear. Following the coronavirus disease (COVID‐19) …
Part 1: Mucormycosis: prevalence, risk factors, clinical features, and diagnosis
JP Lynch III, MC Fishbein, F Abtin… - Expert Review of Anti …, 2023 - Taylor & Francis
Introduction Mucormycosis (MCR) is caused by filamentous molds within the Class
Zygomycetes and Order Mucorales. Infections can result from inhalation of spores into the …
Zygomycetes and Order Mucorales. Infections can result from inhalation of spores into the …
Epidemiology, pathogenesis, clinical characteristics, and treatment of mucormycosis: a review
M Liang, J Xu, Y Luo, J Qu - Annals of Medicine, 2024 - Taylor & Francis
Aim This review aims to summarize the epidemiology, etiology, pathogenesis, clinical
manifestations, and current diagnostic and therapeutic approaches for mucormycosis. The …
manifestations, and current diagnostic and therapeutic approaches for mucormycosis. The …